Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

2
VolitionRX Ltd's (VNRX) CEO Cameron Reynolds on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Good morning, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRX Limited Second Quarter 2018 Earnings Conference Call. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be opened for questions. [Operator Instructions] This conference is being recorded today, Tuesday, August 14, 2018.
VNRX

40
Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review

2018-08-14 seekingalpha
Discussion: RedHill Biopharma (RDHL) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The notice allows the patent to be valid until at least 2029. Apart from Crohn’s Disease, the company has diverse program pipeline. The program includes other indications such as H. Pylori infection, migraine, and nontuberculous mycobacteria (NTM) infections.
MBIO REDIF APOP RDHL ACER ARQL MGTX STML CLRBZ CLRBW MCUJF ABBV CLRB APOPW ALNY ABBV VNRX

2
VNRX / VolitionRX Ltd FORM 8-K CURRENT REPORT (Current Report)

2018-08-13 sec.gov
Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION
VNRX

2
VNRX / VolitionRX Ltd FORM 10-Q QUARTERLY REPORT (Quarterly Report)

2018-08-13 sec.gov
Form 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
VNRX

2
VNRX / VolitionRX Ltd FORM 8-K CURRENT REPORT (Current Report)

2018-08-09 sec.gov
Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION
VNRX

2
VNRX / VolitionRX Ltd DEFINITIVE 14A PROXY STATEMENT

2018-07-20 sec.gov
Definitive 14A Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
VNRX

0
SeeThruEquity Issues Update on VolitionRX Ltd. (VNRX) with a Target Price of $7.00

2018-06-04 accesswire
NEW YORK, NY / ACCESSWIRE / June 4, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Volition RX Ltd. with a Target Price of $7.00.
VNRX

170
Top Analyst Upgrades and Downgrades: Celgene, Cypress Semi, Intuit, KemPharm, Oasis Petroleum, Rio Tinto, Shake Shack and More

2018-05-23 247wallst - 6
Stocks were up earlier this week, but fresh warnings that a North Korea summit might not actually happen in June weighed on the indexes on Wednesday. The trend of buying the dips has not worked as well as it has in prior years, and many investors have been considering how they want their investments positioned for the longer term.
RIO CY RIO KOOL KOOLW AEE RTPPF EL SHAK CELG RTNTF MS VNRX CSCWF CELGZ WLL KMPH INTU OAS RIO VIRT TRI

0
VolitionRX Ltd's (VNRX) CEO Cameron Reynolds on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the VolitionRX Limited First Quarter 2018 Earnings Conference Call. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be opened for questions. [Operator Instructions] This conference is being recorded today, Friday, May 11, 2018.
VNRX

6
VNRX / VolitionRX Ltd FORM 8-K CURRENT REPORT (Current Report)

2018-05-10 sec.gov - 6
Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
VNRX

2
VNRX / VolitionRX Ltd FORM 10-Q QUARTERLY REPORT (Quarterly Report)

2018-05-10 sec.gov - 2
Form 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
VNRX

1
VNRX / VolitionRX Ltd CURRENT REPORT ON FORM 8-K (Current Report)

2018-03-12 sec.gov - 1
Current Report on Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
VNRX

Related Articles

REPH: Recro Pharma Analysis and Research Report

23h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 928661107